Page 282 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology WGCNA and LASSO for osteoporosis biomarkers

candidates, further experimental and clinical validation is 5. Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A,
essential to confirm their mechanistic roles and translational Aurora R. T-cell mediated inflammation in postmenopausal
value. These findings provide potential directions for osteoporosis. Front Immunol. 2021;12:687551.
developing diagnostic and therapeutic strategies for OP. doi: 10.3389/fimmu.2021.687551
Acknowledgments 6. Fischer V, Haffner-Luntzer M. Interaction between bone
and immune cells: Implications for postmenopausal
None. osteoporosis. Semin Cell Dev Biol. 2022;123:14-21.
Funding doi: 10.1016/j.semcdb.2021.05.014

None. 7. Tyagi AM, Srivastava K, Mansoori MN, Trivedi R,
Chattopadhyay N, Singh D. Estrogen deficiency induces
Conflict of interest the differentiation of IL-17 secreting Th17 cells: A new
candidate in the pathogenesis of osteoporosis. PLoS One.
The authors declare they have no competing interests. 2012;7(9):e44552.
Author contributions doi: 10.1371/journal.pone.0044552
8. Management of osteoporosis in postmenopausal women:
Conceptualization: Farra Aidah Jumuddin The 2021 position statement of The North American
Formal analysis: Zarina Awang menopause society. Menopause. 2021;28(9):973-997.
Investigation: Cuicui Zhou
Methodology: Cuicui Zhou, Farra Aidah Jumuddin doi: 10.1097/gme.0000000000001831
Writing–original draft: Cuicui Zhou 9. Reid IR. Vitamin D effect on bone mineral density and fractures.
Writing–review & editing: Cuicui Zhou, Zarina Awang Endocrinol Metab Clin North Am. 2017;46(4):935-945.

Ethics approval and consent to participate doi: 10.1016/j.ecl.2017.07.005
10. Weaver CM, Gordon CM, Janz KF, et al. The national
Not applicable.
osteoporosis foundation’s position statement on peak bone
Consent for publication mass development and lifestyle factors: A systematic review
and implementation recommendations. Osteoporos Int.
Not applicable. 2016;27(4):1281-1386.
Availability of data doi: 10.1007/s00198-015-3440-3
11. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s
Data is available from the corresponding author upon guide to prevention and treatment of osteoporosis.
reasonable request. Osteoporos Int. 2022;33(10):2049-2102.

References doi: 10.1007/s00198-021-05900-y
1. Gómez O, Talero AP, Zanchetta MB, et al. Diagnostic, 12. Johnston CB, Dagar M. Osteoporosis in older adults. Med
treatment, and follow-up of osteoporosis-position statement Clin North Am. 2020;104(5):873-884.
of the Latin American federation of endocrinology. Arch doi: 10.1016/j.mcna.2020.06.004
Osteoporos. 2021;16(1):114.
13. Eastell R, Szulc P. Use of bone turnover markers in
doi: 10.1007/s11657-021-00974-x postmenopausal osteoporosis. Lancet Diabetes Endocrinol.
2. Gao S, Zhao Y. Quality of life in postmenopausal women 2017;5(11):908-923.
with osteoporosis: A systematic review and meta-analysis. doi: 10.1016/s2213-8587(17)30184-5
Qual Life Res. 2023;32(6):1551-1565.
14. Li H, Xiao Z, Quarles LD, Li W. Osteoporosis: Mechanism,
doi: 10.1007/s11136-022-03281-1 molecular target and current status on drug development.
3. Compston JE, McClung MR, Leslie WD. Osteoporosis. Curr Med Chem. 2021;28(8):1489-1507.
Lancet. 2019;393(10169):364-376.
doi: 10.2174/0929867327666200330142432
doi: 10.1016/s0140-6736(18)32112-3 15. Lo HJ, Tsai CH, Huang TW. Apoptosis-associated genetic
4. Clynes MA, Harvey NC, Curtis EM, Fuggle NR, mechanisms in the transition from rheumatoid arthritis
Dennison EM, Cooper C. The epidemiology of osteoporosis. to osteoporosis: A bioinformatics and functional analysis
Br Med Bull. 2020;133(1):105-117. approach. APL Bioeng. 2024;8(4):046107.
doi: 10.1093/bmb/ldaa005 doi: 10.1063/5.0233961

Volume 9 Issue 3 (2025) 274 doi: 10.36922/EJMO025240252